AIS announces launch of a new spectral imaging platform ScanView, designed and manufactured by Applied Spectral Imaging (ASI), Israel.The ScanView system is intended for in-vitro diagnostic use as an adjunctive automated enumeration tool to assist the cytogenetics and pathologist to detect amplifications of the HER-2/neu gene in human breast cancer specimens.
A new application for the ScanView System will assist caregivers in the analysis of the FISH signals in tissue specimens of breast cancer patients. This test is an important factor in the evaluation and selection of certain breast cancer patients for Genentech's Herceptin (Trastuzumab) therapy.
The ScanView system has previously received FDA clearance as an aiding tool in counting and classifying fluorescent signals in interphase nuclei with the Vysis CEP XY Probes.
In addition, the United States Food and Drug Administration (FDA) has recently approved ScanView Scanning Platform for Detection and Quantifying HER-2/neu gene via Fluorescence In Situ Hybridization (FISH) in interphase nuclei from formalin-fixed, paraffin embedded human breast cancer tissue specimens, probed by the Vysis PathVysion™ Her-2 DNA Probe Kit.
No comments:
Post a Comment